New cell therapy methods for treating resistant melanoma
Official title: Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma
Funded at Sloan-Kettering Inst Can Research · NIH-10932898 · Data updated 2026-11-12
This study is looking for new ways to help patients with melanoma that hasn't improved with regular treatments by finding special markers in their tumors and using them to create targeted therapies that boost the immune system, and patients may have a chance to join trials testing these exciting new options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $430,781 |
| NIH project number | 5R01CA286507-02 |
| Project ID | NIH-10932898 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with melanoma that has specific genetic mutations, particularly those resistant to current therapies.
✕Less likely to help
Patients with melanoma that is not genetically defined or those who have not undergone prior treatments may not benefit from this research.
What this research studies
This research focuses on developing innovative cell therapy approaches specifically for patients with melanoma that has not responded to standard treatments. It aims to identify unique antigens in melanoma tumors with specific mutations and create targeted therapies that can effectively engage the immune system. By utilizing T cell receptor-based immunotherapy, the project seeks to overcome the challenges posed by genetic mutations that hinder treatment effectiveness. Patients may have the opportunity to participate in trials that explore these new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with therapy-resistant melanoma, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Klebanoff, Christopher Austin — Sloan-Kettering Inst Can Research
- Study coordinator: Klebanoff, Christopher Austin
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.